EpiPen Manufacturer Will Be A No-Show At Senate Hearing

FILE - In this July 8, 2016, file photo, a pharmacist holds a package of EpiPen epinephrine auto-injectors, a Mylan product, in Sacramento, Calif. On Wednesday, Nov. 9, 2016, Mylan Inc. reported company earnings. (AP... FILE - In this July 8, 2016, file photo, a pharmacist holds a package of EpiPen epinephrine auto-injectors, a Mylan product, in Sacramento, Calif. On Wednesday, Nov. 9, 2016, Mylan Inc. reported company earnings. (AP Photo/Rich Pedroncelli, File) MORE LESS
Start your day with TPM.
Sign up for the Morning Memo newsletter

WASHINGTON (AP) — Senate Judiciary Chairman Charles Grassley says pharmaceutical company Mylan is declining to testify at his committee’s hearing next week on a settlement between the company and the Justice Department over its life-saving Epi-Pen.

Grassley on Monday released a letter from an attorney for Mylan saying officials would not testify. The Nov. 18 letter said company executives wouldn’t testify because the settlement is a pending matter and the Justice Department would also not be attending.

Mylan will pay $465 million to settle allegations that it overbilled Medicaid for EpiPen. At issue was whether the product should have been classified as generic under a Medicaid program.

The list price of EpiPens had grown to $608 for a two-pack, an increase of more than 500 percent since 2007.

Copyright 2016 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Latest News
Comments
Masthead Masthead
Founder & Editor-in-Chief:
Executive Editor:
Managing Editor:
Associate Editor:
Editor at Large:
General Counsel:
Publisher:
Head of Product:
Director of Technology:
Associate Publisher:
Front End Developer:
Senior Designer: